September 23, 2023

Dana-Far­ber Can­cer In­sti­tute an­nounced on Sept. 14 that it is se­cur­ing a new joint ven­ture with Beth Is­rael Dea­coness Med­ical Cen­ter, mark­ing a breakup of

As Karuna Ther­a­peu­tics wraps up its FDA ap­proval re­quest for what could be the first new type of schiz­o­phre­nia drug in decades, an­oth­er East Coast

Pad­cev, Keytru­da’s con­fir­ma­to­ry win: Astel­las and Seagen said Fri­day that Pad­cev and Mer­ck’s Keytru­da helped cer­tain blad­der can­cer pa­tients live longer than chemother­a­py in a

Abpro, an an­ti­body mak­er work­ing on T cell en­gagers that tar­get HER2+ can­cer types, is go­ing pub­lic through merg­ing with a SPAC com­pa­ny dubbed At­lantic

Gener­ics pro­duc­er Glen­mark Phar­ma­ceu­ti­cals is di­vest­ing al­most com­plete­ly from its ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API)-man­u­fac­tur­ing sub­sidiary, sell­ing 75% of its shares to Nir­ma Lim­it­ed for $7.41

As­traZeneca and Dai­ichi Sankyo’s TROP2-tar­get­ed an­ti­body-drug con­ju­gate has met a key end­point in the Phase III TRO­PI­ON-Breast01 tri­al, bring­ing it one step clos­er to po­ten­tial­ly com­pete

→ David M. Ep­stein is out as CEO of can­cer play­er Black Di­a­mond Ther­a­peu­tics, which is putting chair­man Mark Vel­le­ca in charge. This is Vel­le­ca’s third

The CDC’s advisors on Friday recommended a maternal respiratory syncytial virus (RSV) vaccine to protect infants from serious infections. By an 11-1 vote, the Advisory

Treatment failure with amoxicillin-clavulanate for pediatric acute sinusitis was similar compared with amoxicillin alone, but the broad-spectrum antibiotic may be associated with more adverse events,

Some young European medical students and residents were recently candid with VICE Belgium about their off-duty substance use habits. Using pseudonyms, VICE Belgium detailed how